BRONTE, Giuseppe

BRONTE, Giuseppe  

Dipartimento Scienze Cliniche e Molecolari  

Mostra records
Risultati 1 - 20 di 109 (tempo di esecuzione: 0.031 secondi).
Titolo Data di pubblicazione Autore(i) File
A headlight on liquid biopsies: a challenging tool for breast cancer management 1-gen-2016 Massihnia, D.; Perez, A.; Bazan, V.; Bronte, G.; Castiglia, M.; Fanale, D.; Barraco, N.; Cangemi, A.; Di Piazza, F.; Calo, V.; Rizzo, S.; Cicero, G.; Pantuso, G.; Russo, A.
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 1-gen-2012 Santini, D.; Virzi, V.; Vasile, E.; Vincenzi, B.; Catalano, V.; Graziano, F.; Masi, G.; Bronte, G.; Russo, A.; Falcone, A.; Tonini, G.
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 1-gen-2015 Papadimitriou, K.; Antoniou, G.; Rolfo, C.; Russo, A.; Bronte, G.; Vassiliou, V.; Papamichael, D.; Peeters, M.; Kountourakis, P.
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 1-gen-2019 De Matteis, S.; Canale, M.; Verlicchi, A.; Bronte, G.; Delmonte, A.; Crino, L.; Martinelli, G.; Ulivi, P.
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 1-gen-2014 Rolfo, C.; Passiglia, F.; Castiglia, M.; Raez, L. E.; Germonpre, P.; Gil-Bazo, I.; Zwaenepoel, K.; De Wilde, A.; Bronte, G.; Russo, A.; Van Meerbeeck, J. P.; Van Schil, P.; Pauwels, P.
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 1-gen-2013 Fanale, D.; Iovanna, J. L.; Calvo, E. L.; Berthezene, P.; Belleau, P.; Dagorn, J. C.; Ancona, C.; Catania, G.; D'Alia, P.; Galvano, A.; Gulotta, E.; Lo Dico, S.; Passiglia, F.; Bronte, G.; Midiri, M.; Lo Re, G.; Cicero, G.; Bazan, V.; Russo, A.
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 1-gen-2016 Cabibi, D.; Caruso, S.; Bazan, V.; Castiglia, M.; Bronte, G.; Ingrao, S.; Fanale, D.; Cangemi, A.; Calo, V.; Listi, A.; Incorvaia, L.; Galvano, A.; Pantuso, G.; Fiorentino, E.; Castorina, S.; Russo, A.
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 1-gen-2018 Bronte, G.; Bravaccini, S.; Ravaioli, S.; Puccetti, M.; Scarpi, E.; Andreis, D.; Tumedei, M. M.; Sarti, S.; Cecconetto, L.; Pietri, E.; De Simone, V.; Maltoni, R.; Bonafe, M.; Amadori, D.; Rocca, A.
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 1-gen-2018 Bronte, G.; Rocca, A.; Ravaioli, S.; Puccetti, M.; Tumedei, M. M.; Scarpi, E.; Andreis, D.; Maltoni, R.; Sarti, S.; Cecconetto, L.; Fedeli, A.; Pietri, E.; De Simone, V.; Asioli, S.; Amadori, D.; Bravaccini, S.
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 1-gen-2016 Bronte, G.; Passiglia, F.; Galvano, A.; Russo, A.
Anti-endothelin drugs in solid tumors 1-gen-2010 Russo, A.; Bronte, G.; Rizzo, S.; Fanale, D.; Di Gaudio, F.; Gebbia, N.; Bazan, V.
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 1-gen-2014 Bronte, G.; Rolfo, C.; Giovannetti, E.; Cicero, G.; Pauwels, P.; Passiglia, F.; Castiglia, M.; Rizzo, S.; Vullo, F. L.; Fiorentino, E.; Van Meerbeeck, J.; Russo, A.
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 1-gen-2018 Bravaccini, S.; Ravaioli, S.; Amadori, D.; Scarpi, E.; Puccetti, M.; Rocca, A.; Tumedei, M. M.; Masalu, N.; Kahima, J.; Pangan, A.; Faustine, L.; Farolfi, A.; Maltoni, R.; Bonafe, M.; Serra, P.; Bronte, G.
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 1-gen-2016 Incorvaia, L.; Bronte, G.; Bazan, V.; Badalamenti, G.; Rizzo, S.; Pantuso, G.; Natoli, C.; Russo, A.
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 1-gen-2013 Rolfo, C.; Raez, L. E.; Bronte, G.; Santos, E. S.; Papadimitriou, K.; Buffoni, L.; Van Meerbeeck, J. P.; Russo, A.
Bortezomib: A new pro-apoptotic agent in cancer treatment 1-gen-2010 Russo, A.; Bronte, G.; Fulfaro, F.; Cicero, G.; Adamo, V.; Gebbia, N.; Rizzo, S.
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 1-gen-2021 Bronte, G.; Cafaro, A.; Pasini, L.; Priano, I.; Andrikou, K.; Cravero, P.; Burgio, M. A.; Delmonte, A.; Crino, L.
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 1-gen-2016 Passiglia, F.; Bronte, G.; Bazan, V.; Galvano, A.; Vincenzi, B.; Russo, A.
Cancer and the microbiome: Potential applications as new tumor biomarker 1-gen-2015 Shahanavaj, K.; Gil-Bazo, I.; Castiglia, M.; Bronte, G.; Passiglia, F.; Carreca, A. P.; Del Pozo, J. L.; Russo, A.; Peeters, M.; Rolfo, C.
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 1-gen-2018 Bronte, E.; Bronte, G.; Novo, G.; Rinaldi, G.; Bronte, F.; Passiglia, F.; Russo, A.